Release date: 2024-08-09 15:49:10 Article From: Lucius Laos Recommended: 104
Pemigatinib is a targeted drug that is mainly used to treat cholangiocarcinoma.
From the perspective of drug specifications, Pemigatinib is available in several different dose versions to meet the treatment needs of different patients. Common sizes include 4.5mg/tablet, 9mg/tablet, and 13.5mg/tablet, and each size usually contains 14 tablets or 21 tablets (depending on the region). These different specifications of drugs have different dosages, but they all belong to the same drug ingredient Pemigatinib, but there are differences in packaging and dosage.
On April 18, 2020, the United States Food and Drug Administration (FDA) granted accelerated approval of Pemazyre (Pemigatinib) oral tablets developed by Incyte for the treatment of adult patients with treatment-experienced advanced cholangiocarcinoma. This is the world's first targeted therapy for cholangiocarcinoma.
On August 26, 2022, the FDA re-approved Pemazyre for the treatment of adults with relapsed or refractory myeloid or lymphoid tumors (MLNs) with FGFR1 rearrangements.
Cholangiocarcinoma is a malignant tumor that occurs in the bile duct system, and its symptoms vary from individual to individual, and the common symptoms include jaundice, abdominal pain, fever, etc.
Jaundice is the most common symptom of cholangiocarcinoma, and about 90%~98% of cholangiocarcinoma patients have varying degrees of skin and scleral jaundancosis. Jaundice may get worse gradually and last longer. Patients with cholangiocarcinoma usually develop jaundice at an early stage, accompanied by symptoms such as itching of the skin all over the body.
About half of the patients have symptoms such as right upper abdominal distension and pain, which can radiate to the back. Abdominal pain may initially resemble symptoms of cholelithiasis or cholecystitis, followed by persistent abdominal pain.
【Warm tips】When patients buy generic drugs, they should choose formal channels to ensure the quality and safety of the drugs. Avoid purchasing counterfeit products from informal sources.
Lung cancer is the most rapidly increasing malignant tumor with the fastest increasing morbidity and···【more】
Recommended:2012024-09-07
On November 14, 2024, the Committee for Medicinal Products for Human Use (CHMP) of the European Medi···【more】
Recommended:1582025-13-01
Recent advancements have reaffirmed the significance of liquid biopsy in the management of advanced ···【more】
Recommended:1562025-06-01
FDA Approves First Generic Version of Victoza (liraglutide injection)The U.S. Food and Drug Administ···【more】
Recommended:1712024-30-12
The new indication involves the treatment of adult patients with locally advanced, unresectable non-···【more】
Recommended:1612024-24-12
he U.S. Food and Drug Administration (FDA) has approved Crenessity (crinecerfont) for use in combina···【more】
Recommended:1462024-17-12
In the phase Ib/II multicenter pivotal FELIX study, the autologous 41BB-ζ anti-CD19 chimeric antigen···【more】
Recommended:1052024-13-12
On 25 July 2024, the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHM···【more】
Recommended:2482024-26-08
Lucius Pharmaceutical Co., Ltd., was established in 2020 in Vientiane, the capital of Laos. It aims to offer safe, effective, and affordable medicines globally. With a factory spanning 25,000 square meters, the company manufactures 200+ generic drugs in diverse therapeutic fields.
Address:No.26 Thongmang village, Xaythany district, Vientiane Capital, Laos
E-mail:laoslucius@gmail.com
Whatsapp: